Please login to the form below

Not currently logged in
Email:
Password:

GSK launches specialist rare diseases unit

GSK has launched a standalone unit to specialise in development and commercialisation of medicines for rare diseases

GlaxoSmithKline (GSK) has launched a standalone unit to specialise in development and commercialisation of medicines for rare diseases.

The unit will be led by Marc Dunoyer, GSK's president of Asia Pacific and chairman of Japan. Dunoyer will work closely with GSK's senior vice president of Drug Discovery, Patrick Vallance.

This specialist unit will leverage existing capabilities and partnerships, such as those made by GSK with specialist companies, Prosensa and JCR Pharmaceuticals during 2009, and will establish further in-licensing opportunities.

As part of the agreement with JCR Pharmaceuticals, a Japanese developer and manufacturer of bioactive products, GSK obtained global rights to a number of enzyme replacement therapies that could, upon approval, be used to treat orphan diseases such as Hunter syndrome, Fabry disease and Gaucher disease. 

Marc Dunoyer said: "In addition to our existing discovery effort, alternative opportunities need to be explored to make treatments available for rare diseases. This complementary approach will combine our existing global expertise with specialist partners. Over time, this new unit has the potential to deliver multiple therapies responding to high medical needs of underserved populations of patients." 

Data from Orpha.net, a portal for rare diseases and orphan drugs, shows that over 5,500 rare diseases have been identified. Of these, less than 10 per cent are currently being treated. Many rare diseases are genetic in origin, start in childhood and cause lifelong debility and premature death.

4th February 2010

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Cello Health

Cello Health are expert navigators, helping healthcare clients uncover hidden insights, explore scientific options and make difficult strategic choices...

Latest intelligence

A uniquely English genomic medicine service
The UK National Health Service is developing one standardised approach to embedding precision medicine across the whole of England. Blue Latitude Health speaks to Dr Tom Fowler, Deputy Chief Scientist...
Blended Intelligence
Data is the most valued commodity of the modern world. For P&P it's all about the application....
The relevance of patient perspectives to value: Patient Involvement in Health Technology Assessment
Exploring the evolution of patient involvement in health technology assessment (HTA), and the role of the patient voice in market access....

Infographics